Tetraphase Pharmaceuticals (TTPH) PT Raised to $48 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Tetraphase Pharmaceuticals (TTPH) PT Raised to $40 at Cantor Fitzgerald
December 18, 2014 8:05 AM ESTCantor Fitzgerald analyst Daniel Brims reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $40.00 (from $26.00) after the IGNITE1 study in cIAI met the primary endpoint.
Brims commented, "The phase 3 IGNITE1 study enrolled 541 patients to test the non-inferiority of eravacycline against the standard of care,... More
Tetraphase Pharmaceuticals (TTPH) PT Raised to $45 at Guggenheim
December 18, 2014 7:50 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $45.00 (from $33.00) following positive top-line IGNITE 1 results.
Chen commented, "We are increasing our price target for TTPH from $33 to $45 following positive top-line eravacycline... More
Tetraphase Pharmaceuticals (TTPH) Target Raised to $46 at Needham & Company
December 18, 2014 7:29 AM ESTNeedham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $46.00 (from $28.00) following positive Phase 3 Eravacycline results in cIAI.
Tetraphase announced positive results yesterday from its Phase 3 trial of IV eravacycline in complicated Intra-abdominal... More
Tetraphase Pharmaceuticals (TTPH) PT Raised to $51 at Wedbush
December 18, 2014 7:20 AM ESTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $51.00 (from $31.00) after Eravacycline hits its endpoints in Phase III study for abdominal infections (cIAI).
Behanna noted information on the call was sparse ahead of data... More
Tetraphase Pharma (TTPH) Announces Positive Phase 3 IGNITE 1 Results
December 17, 2014 4:04 PM ESTTetraphase Pharma (Nasdaq: TTPH) announced positive top-line results from IGNITE 1, the Companys Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem. In the trial, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit, under the guidance... More
